Celebrex

News Celebrex

• Creabilis Appoints Dr. Eliot Forster as its New Chief Executive Officer

  Creabilis SA announced the appointment of Eliot Forster as its new Chief Executive Officer. Dr Forster brings to Creabilis significant drug development experience having brought a number of molecules to market. Dr Forster has close to 20 years industry experience in biotechnology and pharmaceutical more

• Common anti-inflammatory drug could help prevent skin cancers, Stanford researcher says

  A widely-available anti-inflammatory prescription drug can reduce the risk of a common skin cancer in humans, according to a researcher at Stanford's School of Medicine. Although oral administration of the drug, celecoxib, is associated with an increased risk of heart attack and stroke in some peopl more

• New understanding of COX-1 and COX-2 enzymes could lead to revised classification of pain meds, Queen's study shows

  COX-1 and COX-2 enzymes may be blocked by pain medications such as Advil and Vioxx in a more complex manner than was previously understood, a Queen's University study has found. "The results of the study have potential implications for how we classify the commonly used anti-inflammatory and pain dr more

Publications Celebrex

• Silica-Lipid Hybrid (SLH) Versus Non-lipid Formulations for Optimising the Dose-Dependent Oral Absorption of Celecoxib

  ABSTRACT Purpose To investigate the dose linearity of celecoxib (CEL) pharmacokinetics from various non-lipid and lipid-based formulations; to probe the mechanisms of CEL absorption from a nano-structured silica-lipid hybrid (SLH) microparticle dosage form. Methods Single-dose pharmacokinetic parame more

• Application of a Biphasic Test for Characterization of In Vitro Drug Release of Immediate Release Formulations of Celecoxib and Its Relevance to In Vivo Absorption

  A biphasic in vitro test method was used to examine release profiles of a poorly soluble model drug, celecoxib (CEB), from its immediate release formulations. Three formulations of CEB were investigated in this study, including a commercial Celebrex capsule, a solution formulation (containing cosolv more

• Application of a Biphasic Test for Characterization of In Vitro Drug Release of Immediate Release Formulations of Celecoxib and Its Relevance to In Vivo Absorption

  A biphasic in vitro test method was used to examine release profiles of a poorly soluble model drug, celecoxib (CEB), from its immediate release formulations. Three formulations of CEB were investigated in this study, including a commercial Celebrex capsule, a solution formulation (containing cosolv more

Market studies Celebrex

• Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014

  GBI Research, the leading business intelligence provider, has released its latest report, “Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014”. The report is built using data and information sourced from proprietary databas more

• Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications

  GBI Research’s new report, “Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications”, provides an expert insight into the global arthritis market and market forecast until 2018. T more

• Saudi Arabia Pharmaceuticals and Healthcare Report Q1 2012

  BMI View: The Saudi market is extremely appealing to multinational drugmakers as it is set to experience rapid growth in demand for healthcare and is the largest market in the Middle East. However, it has been difficult for multinationals to penetrate in the past as the authorities insist on foreign more

Websites Celebrex